The present specification relates to a whitening composition containing a novel quercetin-based compound isolated from post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the whitening composition can be widely utilized in fields associated with skin whitening and skin care.

The present specification relates to a whitening composition containing a novel quercetin-based compound isolated from post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the whitening composition can be widely utilized in fields associated with skin whitening and skin care.

The present technology relates to a nutritional formulation for administration to bariatric individuals. The nutritional formulation includes a multi-nutrients dosage unit; and a minerals dosage unit.

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

The invention disclosed herein relates to synergistic nutritional compositions for enhancing cellular ATP efficiency. Particularly, the invention relates to a synergistic, efficient, nutritional composition for promoting cellular ATP production comprising a therapeutically active exogenous combination of a stabilized oxaloacetate and a biotin-manganese complex along with pharmaceutically acceptable excipients; wherein the stabilized oxaloacetate and the biotin-manganese or salts thereof are present in a weight ratio ranging from 1:0.01 to 1:0.2. Further, the present synergistic nutritional composition is useful for treating ATP deficiency disorders, age-related metabolic disorders, neurodegenerative diseases, cardiovascular diseases, bone related disorders, central nervous system diseases, cognitive disorders and like thereof.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing allergies and/or treating allergies and/or reducing the occurrence or the risk of allergies in an infant or a young child born from a mother deficient in at least one fucosylated oligosaccharide(s) or fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s). The use of said composition in infant formula, milk fortifier or children's food is foreseen.

The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing allergies and/or treating allergies and/or reducing the occurrence or the risk of allergies in an infant or a young child born from a mother deficient in at least one fucosylated oligosaccharide(s) or fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s). The use of said composition in infant formula, milk fortifier or children's food is foreseen.

A supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals is disclosed. The supplement is in a gel form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise a vegetable oil, B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. The amount of mastic gum is from about 1 to about 6 grams per 10 cubic centimeters of gel.